Spinal Cord Injury - Pipeline Review, H1 2018 by MarketResearchReports.biz
"The Report Spinal Cord
Injury - Pipeline Review, H1 2018 provides information on pricing,
market analysis, shares, forecast, and company profiles for key
industry participants. - MarketResearchReports.biz"
About
Spinal
Cord Injury
Market
Global Markets Direct's latest
Pharmaceutical and Healthcare disease pipeline guide Spinal Cord
Injury - Pipeline Review, H1 2018, provides an overview of the Spinal
Cord Injury (Central Nervous System) pipeline landscape.
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/1731742
Spinal cord injury (SCI) is
defined as damage or trauma caused to the spinal cord. SCI can lead
to loss or impaired function resulting in reduced mobility or
feeling. It is usually caused by trauma, transverse myelitis, polio,
spina bifida or Friedreich's ataxia.
Signs and symptoms of spinal cord
injury include extreme back pain or pressure in the neck, head or
back, paralysis in any part of the body, numbness, tingling or loss
of sensation in the hands, fingers, feet or toes, loss of bladder or
bowel control, difficulty in walking and impaired breathing after
injury.
Report Highlights
Global Markets Direct's
Pharmaceutical and Healthcare latest pipeline guide Spinal Cord
Injury - Pipeline Review, H1 2018, provides comprehensive information
on the therapeutics under development for Spinal Cord Injury (Central
Nervous System), complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type. The guide covers the descriptive pharmacological
action of the therapeutics, its complete research and development
history and latest news and press releases.
The Spinal Cord Injury (Central
Nervous System) pipeline guide also reviews of key players involved
in therapeutic development for Spinal Cord Injury and features
dormant and discontinued projects. The guide covers therapeutics
under Development by Companies /Universities /Institutes, the
molecules developed by Companies in Phase III, Phase II, Phase I,
IND/CTA Filed, Preclinical and Discovery stages are 2, 7, 10, 1, 29
and 4 respectively. Similarly, the Universities portfolio in Phase I
and Preclinical stages comprises 1 and 13 molecules, respectively.
Request
for TOC @
https://www.marketresearchreports.biz/reports/1731742/spinal-cord-injury-pipeline-review-h1-2018-market-research-reports/toc
Spinal Cord Injury (Central
Nervous System) pipeline guide helps in identifying and tracking
emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage. The guide is built using
data and information sourced from Global Markets Directs proprietary
databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third
party sources. Additionally, various dynamic tracking processes
ensure that the most recent developments are captured on a real time
basis.
Note: Certain content / sections
in the pipeline guide may be removed or altered based on the
availability and relevance of data.
Scope
- The pipeline guide provides a
snapshot of the global therapeutic landscape of Spinal Cord Injury
(Central Nervous System).
- The pipeline guide reviews
pipeline therapeutics for Spinal Cord Injury (Central Nervous System)
by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- The pipeline guide covers
pipeline products based on several stages of development ranging from
pre-registration till discovery and undisclosed stages.
- The pipeline guide features
descriptive drug profiles for the pipeline products which comprise,
product description, descriptive licensing and collaboration details,
R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key
companies involved in Spinal Cord Injury (Central Nervous System)
therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates
Spinal Cord Injury (Central Nervous System) therapeutics based on
mechanism of action (MoA), drug target, route of administration (RoA)
and molecule type.
- The pipeline guide encapsulates
all the dormant and discontinued pipeline projects.
- The pipeline guide reviews
latest news related to pipeline therapeutics for Spinal Cord Injury
(Central Nervous System)
Reasons to buy
- Procure strategically important
competitor information, analysis, and insights to formulate effective
R&D strategies.
- Recognize emerging players with
potentially strong product portfolio and create effective
counter-strategies to gain competitive advantage.
- Find and recognize significant
and varied types of therapeutics under development for Spinal Cord
Injury (Central Nervous System).
- Classify potential new clients
or partners in the target demographic.
- Develop tactical initiatives by
understanding the focus areas of leading companies.
- Plan mergers and acquisitions
meritoriously by identifying key players and its most promising
pipeline therapeutics.
- Formulate corrective measures
for pipeline projects by understanding Spinal Cord Injury (Central
Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing
and out-licensing strategies by identifying prospective partners with
the most attractive projects to enhance and expand business potential
and scope.
- Adjust the therapeutic portfolio
by recognizing discontinued projects and understand from the know-how
what drove them from pipeline.
View
Report @
https://www.marketresearchreports.biz/reports/1731742/spinal-cord-injury-pipeline-review-h1-2018-market-research-reports
Table of Contents
Table of Contents 2
Introduction 5
Spinal Cord Injury - Overview 6
Spinal Cord Injury - Therapeutics
Development 7
Spinal Cord Injury - Therapeutics
Assessment 17
Spinal Cord Injury - Companies
Involved in Therapeutics Development 27
Spinal Cord Injury - Drug Profiles
41
Spinal Cord Injury - Dormant
Projects 172
Spinal Cord Injury - Discontinued
Products 177
Spinal Cord Injury - Product
Development Milestones 178
Appendix 189
List of Tables
Number of Products under
Development for Spinal Cord Injury, H1 2018
Number of Products under
Development by Companies, H1 2018
Number of Products under
Development by Universities/Institutes, H1 2018
Products under Development by
Companies, H1 2018
Products under Development by
Universities/Institutes, H1 2018
Number of Products by Stage and
Target, H1 2018
Number of Products by Stage and
Mechanism of Action, H1 2018
Number of Products by Stage and
Route of Administration, H1 2018
Number of Products by Stage and
Molecule Type, H1 2018
Spinal Cord Injury - Pipeline by
AbbVie Inc, H1 2018
Spinal Cord Injury - Pipeline by
Acorda Therapeutics Inc, H1 2018
Spinal Cord Injury - Pipeline by
Asterias Biotherapeutics Inc, H1 2018
Spinal Cord Injury - Pipeline by
Athersys Inc, H1 2018
Spinal Cord Injury - Pipeline by
BioArctic AB, H1 2018
Spinal Cord Injury - Pipeline by
BioAxone BioSciences Inc, H1 2018
Spinal Cord Injury - Pipeline by
Biogen Inc, H1 2018
Spinal Cord Injury - Pipeline by
CSL Ltd, H1 2018
Spinal Cord Injury - Pipeline by
CSPC Pharmaceutical Group Limited, H1 2018
Spinal Cord Injury - Pipeline by
Genervon Biopharmaceuticals LLC, H1 2018
Spinal Cord Injury - Pipeline by
Hemostemix Inc, H1 2018
Spinal Cord Injury - Pipeline by
Histocell SL, H1 2018
Spinal Cord Injury - Pipeline by
K-Stemcell Co Ltd, H1 2018
Spinal Cord Injury - Pipeline by
Kadimastem Ltd, H1 2018
Spinal Cord Injury - Pipeline by
Kringle Pharma Inc, H1 2018
Spinal Cord Injury - Pipeline by
MandalMed Inc, H1 2018
Spinal Cord Injury - Pipeline by
Mapreg SAS, H1 2018
Spinal Cord Injury - Pipeline by
Neuralstem Inc, H1 2018
Spinal Cord Injury - Pipeline by
Neuronax SAS, H1 2018
Spinal Cord Injury - Pipeline by
New World Laboratories Inc, H1 2018
Spinal Cord Injury - Pipeline by
Pharmicell Co Ltd, H1 2018
Spinal Cord Injury - Pipeline by
PixarBio Corp, H1 2018
Spinal Cord Injury - Pipeline by
RDD Pharma Ltd, H1 2018
Spinal Cord Injury - Pipeline by
RespireRx Pharmaceuticals Inc, H1 2018
Spinal Cord Injury - Pipeline by
SanBio Inc, H1 2018
Spinal Cord Injury - Pipeline by
Spectrum Pharmaceuticals Inc, H1 2018
Spinal Cord Injury - Pipeline by
Stemedica Cell Technologies Inc, H1 2018
Spinal Cord Injury - Pipeline by
Sumitomo Dainippon Pharma Co Ltd, H1 2018
Spinal Cord Injury - Pipeline by
TissueGene Inc, H1 2018
Spinal Cord Injury - Pipeline by
Tumorend LLC, H1 2018
Spinal Cord Injury - Pipeline by
Vertex Pharmaceuticals Inc, H1 2018
Spinal Cord Injury - Pipeline by
Vicore Pharma AB, H1 2018
Spinal Cord Injury - Dormant
Projects, H1 2018
Spinal Cord Injury - Discontinued
Products, H1 2018
List of Figures
Number of Products under
Development for Spinal Cord Injury, H1 2018
Number of Products under
Development by Companies, H1 2018
Number of Products under
Development by Universities/Institutes, H1 2018
Number of Products by Top 10
Targets, H1 2018
Number of Products by Stage and
Top 10 Targets, H1 2018
Number of Products by Top 10
Mechanism of Actions, H1 2018
Number of Products by Stage and
Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of
Administration, H1 2018
Number of Products by Stage and
Routes of Administration, H1 2018
Number of Products by Top 10
Molecule Types, H1 2018
Number of Products by Stage and
Top 10 Molecule Types, H1 2018
About us
MarketResearchReports.biz is the
most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Comments
Post a Comment